Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. Its mission involves discovering, advancing, and bringing to market innovative therapeutic solutions for individuals battling solid tumor cancers. The company's pipeline features several key candidates, including Cosibelimab, a leading fully-human IgG1 monoclonal antibody. This therapy is designed to directly bind to programmed death ligand-1 (PD-L1), thereby inhibiting its interaction with programmed death receptor-1 and B7.1 receptors. Another significant antibody in development is CK-302, a human agonistic antibody intended to bind and activate signaling within GITR-expressing cells. Beyond antibodies, Checkpoint Therapeutics is advancing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR mutation-positive non-small cell lung cancer. Its portfolio also includes CK-103, a highly selective and potent small molecule designed to inhibit bromodomain and extra-terminal (BET) bromodomains. Furthermore, a fully human, preclinical anti-carbonic anhydrase IX (CAIX) antibody is being developed, which aims to identify and destroy CAIX-expressing cells through both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To broaden its reach, Checkpoint Therapeutics has established collaboration agreements with TG Therapeutics, Inc. These partnerships focus on the joint development and commercialization of specific assets related to its licenses in the area of hematological malignancies. Established in 2014, Checkpoint Therapeutics is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Fortress Biotech, Inc.


Net sales
Gross margin
Net income